S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
NASDAQ:OVID

Ovid Therapeutics (OVID) Stock Price, News & Analysis

$3.23
+0.02 (+0.62%)
(As of 04/19/2024 ET)
Today's Range
$3.17
$3.29
50-Day Range
$2.72
$4.04
52-Week Range
$2.57
$4.14
Volume
176,642 shs
Average Volume
153,358 shs
Market Capitalization
$228.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Ovid Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
178.6% Upside
$9.00 Price Target
Short Interest
Healthy
4.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$50,364 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.65) to ($0.20) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.54 out of 5 stars

Medical Sector

75th out of 909 stocks

Pharmaceutical Preparations Industry

25th out of 426 stocks

OVID stock logo

About Ovid Therapeutics Stock (NASDAQ:OVID)

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

OVID Stock Price History

OVID Stock News Headlines

Start loving Mondays like this
Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
5 Oversold Biotech Stocks To Buy Right Now
TD Cowen Sticks to Its Buy Rating for Ovid Therapeutics (OVID)
OVID Oct 2024 7.500 call
Recap: Ovid Therapeutics Q4 Earnings
Ovid Therapeutics Inc (OVID)
Ovid-Elsie girls win third straight conference title
OVID Mar 2024 5.000 call
OVID Apr 2024 5.000 call
See More Headlines
Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/08/2024
Today
4/21/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OVID
Fax
N/A
Employees
40
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$11.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+178.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-52,340,000.00
Net Margins
-13,351.53%
Pretax Margin
-13,351.79%

Debt

Sales & Book Value

Annual Sales
$390,000.00
Book Value
$1.24 per share

Miscellaneous

Free Float
61,801,000
Market Cap
$228.39 million
Optionable
Optionable
Beta
0.71

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Jeremy Max Levin Ba Zoology (Age 71)
    Dphil, Mb Bchir, President, CEO & Chairman
    Comp: $923.54k
  • Mr. Jeffrey A. Rona (Age 56)
    Principal Financial Officer, Principal Accounting Officer & Chief Business and Financial Officer
    Comp: $686.28k
  • Mr. Jason Tardio M.B.A. (Age 46)
    Chief Operating Officer
    Comp: $652.84k
  • Ms. Lora Pike
    Senior Director of Investor Relations & Public Relations
  • Mr. Thomas Michael Perone J.D. (Age 58)
    M.B.A., General Counsel
    Comp: $632.11k
  • Mr. Simon D. Kelner (Age 50)
    Chief Human Resources Officer
  • Dr. Dirk Haasner (Age 59)
    Senior Vice President of Global Manufacturing & CMC QA
    Comp: $416.95k
  • Dr. Todd F. Baumgartner M.D.
    M.P.H., Senior Vice President of Regulatory Affairs
  • Dr. Julia Tsai Ph.D. (Age 49)
    Senior Vice President of Clinical Development
  • Ms. Meg Alexander
    Chief Strategy Officer

OVID Stock Analysis - Frequently Asked Questions

Should I buy or sell Ovid Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OVID shares.
View OVID analyst ratings
or view top-rated stocks.

What is Ovid Therapeutics' stock price target for 2024?

3 brokers have issued 1 year price targets for Ovid Therapeutics' shares. Their OVID share price targets range from $8.00 to $11.00. On average, they expect the company's share price to reach $9.00 in the next year. This suggests a possible upside of 178.6% from the stock's current price.
View analysts price targets for OVID
or view top-rated stocks among Wall Street analysts.

How have OVID shares performed in 2024?

Ovid Therapeutics' stock was trading at $3.22 at the start of the year. Since then, OVID stock has increased by 0.3% and is now trading at $3.23.
View the best growth stocks for 2024 here
.

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 2,800,000 shares, a decline of 23.7% from the March 15th total of 3,670,000 shares. Based on an average trading volume of 205,000 shares, the short-interest ratio is presently 13.7 days. Approximately 4.8% of the company's stock are short sold.
View Ovid Therapeutics' Short Interest
.

When is Ovid Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our OVID earnings forecast
.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) released its quarterly earnings data on Friday, March, 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.05. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.10 million. Ovid Therapeutics had a negative net margin of 13,351.53% and a negative trailing twelve-month return on equity of 49.76%.

What other stocks do shareholders of Ovid Therapeutics own?
When did Ovid Therapeutics IPO?

Ovid Therapeutics (OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OVID) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners